Biohaven Pharmaceutical Holding Company Ltd. re-affirmed sales guidance for the full year 2022. For the year, the company expected net product sales of $825 million to $900 million.
Biohaven Pharmaceutical Holding Company Ltd.
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.07 USD | -0.45% | -4.49% | -76.90% |
05-31 | Biohaven Insider Bought Shares Worth $996,240, According to a Recent SEC Filing | MT |
05-15 | Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing | MT |
1st Jan change | Capi. | |
---|---|---|
-76.90% | 541M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- BHVN Stock
- News Biohaven Pharmaceutical Holding Company Ltd.
- Biohaven Pharmaceutical Holding Company Ltd. Re-Affirms Sales Guidance for the Full Year 2022